Maze Therapeutics (MAZE) opened Q1 2026 with revenue of US$20 million and a basic EPS loss of US$0.45, alongside a net income loss of US$24.21 million, setting an earnings-season tone that is still firmly focused on managing losses. Over the past few quarters the company has gone from zero reported revenue in each quarter of 2025 to US$20 million in Q1 2026. Quarterly basic EPS has ranged from a loss of US$1.15 in Q1 2025 to a loss of US$0.45 in the latest period, putting the spotlight on how quickly revenue can help absorb Maze Therapeutics' cost base. With the stock at US$26.96, the key question for investors is how quickly those new top line contributions can translate into steadier margins and a clearer path toward narrowing losses.

See our full analysis for Maze Therapeutics.

Next, the focus shifts to how these results line up against the dominant stories around Maze Therapeutics, highlighting where the numbers support those narratives and where they start to push back.

Loss profile still heavy at US$24.2 million

• Q1 2026 net income shows a loss of US$24.2 million, compared with losses between US$30.1 million and US$34.6 million in each quarter of 2025, and trailing 12 month losses of US$122.5 million highlight how much of the new US$20 million revenue is still being absorbed by expenses.
• Critics highlight that Maze Therapeutics is unprofitable and that losses have grown at about 6.9% per year over the past five years, and the Q1 2026 numbers line up with that concern.
  • The loss per share has eased from a basic EPS loss of US$1.15 in Q1 2025 to a loss of US$0.45 in Q1 2026, yet trailing 12 month EPS is still a loss of US$2.49 which underscores that the business is not close to break even.
  • Forecasts suggest earnings could decline by about 10% per year over the next three years and that Maze Therapeutics is not expected to be profitable in that period, so the current loss run rate remains a central part of the bearish case.

Revenue momentum meets forecasted earnings pressure

• The trailing 12 month view shows US$20 million of revenue against a loss of US$122.5 million and analysts forecast revenue growth of about 64.8% per year while earnings are forecast to decline by roughly 10% per year over the next three years, so top line progress is not yet matched by profit expectations.
• Supporters of a more growth-focused view point to that 64.8% forecast revenue growth, and the move from zero quarterly revenue in 2025 to US$20 million in Q1 2026, but the same forecasts highlight clear tension between the bullish focus on sales and the path to profitability.
  • On the positive side, revenue appearing in Q1 2026 after four consecutive quarters at US$0 suggests the company is starting to generate sales that can contribute to funding the cost base, while prior trailing 12 month revenue of US$167.5 million in early 2025 shows Maze Therapeutics has previously reported material revenue periods.
  • On the cautious side, trailing 12 month net income moved from a gain of US$3.1 million in early 2025 to a loss of US$122.5 million by Q1 2026, which heavily reinforces the bearish concern that strong revenue projections alone do not resolve the current earnings pressure.

Valuation, dilution and volatility in focus at US$26.96

• With the stock at US$26.96, Maze Therapeutics is trading on a P/B of 4.4x compared with 2.6x for the US Pharmaceuticals industry and a peer average of 3.2x, while shareholders have already experienced dilution in the past year and the share price has been more volatile than the broader US market over the last three months.
• Bears argue that paying a higher P/B multiple for a company that is unprofitable today and not expected to be profitable in the next three years leaves little room for error, and the available figures back up why they focus so much on valuation risk.
  • The combination of ongoing losses, with trailing 12 month net income at a loss of US$122.5 million, and prior shareholder dilution means existing holders carry both earnings and ownership risk while the stock trades above industry and peer book value levels.
  • Short term share price volatility adds another layer for those concerns because any negative read across from earnings, forecasts, or financing could move a higher multiple stock more sharply than a lower multiple, more stable peer with similar fundamentals.

To see how other investors weigh Maze Therapeutics' growth, valuation and risk profile around these results, and how sentiment compares across companies in similar situations, check out what the community is saying in real time with the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Maze Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

After weighing both the cautious and optimistic takes in this article, the next move is to look at the underlying data yourself and move quickly from headline impressions to your own judgment. To help you balance the red flags against the potential upside, start by reviewing the 1 key reward and 4 important warning signs.

See What Else Is Out There

Maze Therapeutics is still carrying steep losses of US$122.5 million over the past 12 months, with earnings forecasts pointing to further pressure rather than improvement.

If you want ideas where balance sheets help cushion earnings risk instead of amplifying it, start comparing companies in the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.